Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 3.5% from a year ago
Net receivables stood at $24.35M at the end of Q1 FY2026, down 3.5% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.
Context
- Net receivables amounted to 3.3% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -3.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 30.65M USD
- Year-over-year change
- -5.4%
- 4-year CAGR
- +9.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.65M | -5.4% |
| FY2024 | 2024-12-31 | 32.39M | +23.7% |
| FY2023 | 2023-12-31 | 26.18M | +22.8% |
| FY2022 | 2022-12-31 | 21.33M | +0.9% |
| FY2021 | 2021-12-31 | 21.14M | — |
Net Receivables vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -3.5% is the 6th highest of 7, against a peer median of +49.2%.
- Net receivables amounts to 3.3% of total assets for OCUL, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.16B USD | +6.6% | +18.9% | 8.4% | |
| Jun 2026 | $138.9M USD | +67.4% | +44.4% | 15.1% | |
| Mar 2026 | $101.26M USD | +31.0% | +158.9% | 24.1% | |
| Apr 2026 | $85.69M USD | +100.7% | -6.1% | 19.0% | |
| Mar 2026 | $24.35M USD | -3.5% | +12.9% | 3.3% | |
| Mar 2026 | $2.72M USD | — | — | 12.4% | |
| Mar 2026 | CHF 1.57M CHF | -38.7% | — | 0.6% | |
| Mar 2026 | $1.16M USD | +161.8% | -65.2% | 0.4% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $653K USD | — | — | 0.3% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OCUL) | — | +49.2% | +18.9% | 4.5% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 21.14M | 21.33M | 26.18M | 32.39M | 30.65M |
| Inventory | 1.25M | 1.97M | 2.31M | 3.04M | 3.56M |
| Other Current Assets | 0 | 4.03M | 7.94M | 13.46M | 10.86M |
| Total Current Assets | 191.3M | 129.63M | 232.24M | 440.99M | 782.13M |
| Property, Plant & Equipment (Net) | 11.82M | 17.9M | 18.21M | 15.33M | 24.31M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 1.61M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.76M | 1.76M | 1.61M | 1.61M | 0 |
| Total Non-current Assets | 13.59M | 19.66M | 19.83M | 16.95M | 25.93M |
| Total Assets | 204.89M | 149.29M | 252.06M | 457.94M | 808.06M |
| Account Payables | 4.59M | 5.12M | 4.39M | 4.18M | 4.15M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.82M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 576K | 255K | 128K | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 25.86M |
| Total Current Liabilities | 26.34M | 31.4M | 34.9M | 41.35M | 50.81M |
| Long-term Debt | 51.44M | 54.01M | 74.93M | 68.51M | 74.15M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 13M | 13.39M | 14.14M | 14M | 14M |
| Other Non-current Liabilities | 20.19M | 6.44M | 30.1M | 13.39M | 11.98M |
| Total Non-current Liabilities | 90.55M | 82.52M | 126.03M | 101.24M | 102.94M |
| Total Liabilities | 116.89M | 113.91M | 160.93M | 142.59M | 153.75M |
| Common Stock | 8K | 8K | 12K | 16K | 22K |
| Retained Earnings | (545.8M) | (616.84M) | (697.58M) | (891.08M) | (1.16B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 88M | 35.38M | 91.13M | 315.34M | 654.31M |
| Total Debt | 58.98M | 64.28M | 83.39M | 75.78M | 79.78M |
| Net Debt | (105.18M) | (38.02M) | (112.42M) | (316.32M) | (657.28M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.